InsiderSignal.AI

InsiderSignal.ai

HRTX - Heron Therapeutics, Inc. /De/

Insider Purchase by Morgan Adam (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Morgan Adam, serving as Dir at Heron Therapeutics, Inc. /De/ (HRTX), purchased 1,766,546 shares at $1.50 per share, for a total transaction value of $2,649,819.00. Following this transaction, Morgan Adam now holds 8,823,067 shares of HRTX.

This purchase represents a 25.00% increase in Morgan Adam's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, August 8, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, August 12, 2025, 4 days after the trade was made.

Heron Therapeutics, Inc. /De/ operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Morgan Adam

Dir

Adam Morgan (full name: Adam Joseph Morgan) is a prominent healthcare investor serving as Chairman of the Board of Directors at Heron Therapeutics, Inc. (HRTX) since April 2023[[1]](https://www.biospace.com/heron-therapeutics-announces-new-ceo-and-board-chairman)[[2]](https://rocketreach.co/adam-morgan-email_44141729)[[3]](https://in.marketscreener.com/business-leaders/ADAM-MORGAN-0HPZNH-E/biography/). He is also the Chief Investment Officer and Managing Member of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia[[1]](https://www.biospace.com/heron-therapeutics-announces-new-ceo-and-board-chairman)[[2]](https://rocketreach.co/adam-morgan-email_44141729). Additionally, Morgan serves on the boards of Alimera Sciences, Inc. (as a director and Compensation Committee member), Health Outlook Corporation (as director and Audit Committee chair), and Avego Healthcare Capital LLC[[1]](https://www.biospace.com/heron-therapeutics-announces-new-ceo-and-board-chairman)[[3]](https://in.marketscreener.com/business-leaders/ADAM-MORGAN-0HPZNH-E/biography/)[[4]](https://www.marketscreener.com/insider/ADAM-MORGAN-A2BX8M/). Morgan's career includes prior roles as Senior Analyst at Broadfin Capital, LLC (2018-2020, covering biotech and pharmaceuticals) and Iguana Healthcare Partners LLC (2015-2018, medical devices and specialty pharma), Analyst at Pura Vida Investments, LLC (2014-2015, global medical devices), and Research Associate at Cowen and Company (2014)[[1]](https://www.biospace.com/heron-therapeutics-announces-new-ceo-and-board-chairman). He holds a B.S. in Chemistry and an MBA from the University of Minnesota's Carlson School of Management[[1]](https://www.biospace.com/heron-therapeutics-announces-new-ceo-and-board-chairman). As a significant shareholder in HRTX, Morgan owns over 7 million shares valued at approximately $13 million (as of mid-2023 data) and has engaged in insider transactions, including a major acquisition in July 2023[[5]](https://www.gurufocus.com/insider/226255/adam-morgan).

View full insider profile →

Trade Price

$1.50

Quantity

1,766,546

Total Value

$2,649,819.00

Shares Owned

8,823,067

Trade Date

Friday, August 8, 2025

198 days ago

SEC Filing Date

Tuesday, August 12, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Heron Therapeutics, Inc. /De/

Company Overview

No company information available
View news mentioning HRTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/123325

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime